Libido Clinical Trial
Official title:
A Single-Group, Open-Label Clinical Study to Evaluate the Efficacy of Four Supplements on Improving Readiness for Intimacy
Verified date | May 2023 |
Source | 906 CMVI Holdings |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate the efficacy of four supplements designed to help participants get ready for sexual intimacy through improving digestion, weight management, sexual drive and stamina, and physical endurance during workouts and overall mood and quality of life. This study will be conducted as a single group, virtual trial, in which all participants will take all four supplements and complete online questionnaires. Participants will take the indicated supplements for the indicated amounts of time over 12 weeks. Questionnaires will be completed at baseline, and then at indicated times throughout the trial.
Status | Active, not recruiting |
Enrollment | 36 |
Est. completion date | June 13, 2023 |
Est. primary completion date | June 6, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 44 Years |
Eligibility | Inclusion Criteria: - Male (biological at birth) within the LGBTQIA+ community - Aged between 18-44 - Generally healthy - don't live with any uncontrolled chronic disease - Generally active lifestyle or seeking to achieve health improvement - Sexually active with a partner Exclusion Criteria: - Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. - Anyone with known severe allergic reactions. - Unwilling to follow the study protocol. - Currently experiencing significant symptoms of a mental disorder that might interfere with study participation (e.g. eating disorder, obsessive-compulsive disorder, posttraumatic stress syndrome, bipolar disorder) - Current substance abuse disorder - Diagnosis of an autoimmune disease, such as multiple sclerosis and rheumatoid arthritis - Self-reported or diagnosed high blood pressure or hypotension (BP < 90 over 60) - Currently, or in the past 6 months, undergoing hormone therapy - Any medical condition that is unstable or uncontrolled - A history of sexual trauma or abuse - Has introduced any new prescription medication or supplements within the past 12 weeks that influence gastrointestinal issues, libido, or testosterone production. |
Country | Name | City | State |
---|---|---|---|
United States | Citruslabs | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
906 CMVI Holdings | Citruslabs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in subject's perception of readiness and confidence for intimacy, and sex drive/arousal [Time Frame: Baseline to 12 weeks] | Survey-based assessment (0-5 scale) of changes in reduction in preparation time for intimacy, sexual arousal, and sexual endurance. | 12 weeks | |
Secondary | Changes in digestion, stamina and endurance during workouts, overall confidence, mood and quality of life [Time Frame: Baseline to 12 weeks] | Survey-based assessment (0-5 scale) of changes in digestion, stamina and endurance during workouts, overall confidence, mood and quality of life. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01977313 -
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
|
N/A | |
Completed |
NCT00566384 -
Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido
|
Phase 2 | |
Completed |
NCT00764881 -
Effects of SH T00658ID on Libido
|
Phase 3 | |
Completed |
NCT05258513 -
The Effects of Geranylgeraniol (GG) Sourced From Annatto on Sexual Health
|
N/A |